Clinical Trials Browser

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT02079220 2017-07-31

A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT02915172 2017-06-26

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Phase 1 Withdrawn

BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

NCT00408772 2017-06-09

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT01227408 2017-05-02

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT03117855 2017-04-18

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

Phase 1 Withdrawn

Gastrointestinal

Cholangiocarcinoma

NCT02586610 2017-01-20

Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms

NCT00450515 2016-12-06

Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00119314 2015-05-27

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Phase 2 Withdrawn

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT01130701 2015-03-17

PMABIIS

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT01293942 2013-06-05

IXO+A in mCRC With Liver-only Metastases

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT00524069 2013-02-01

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Phase NA Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT00503932 2012-03-22

Proton Therapy With Capecitabine for Rectal Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Rectal Neoplasms

NCT00118300 2011-07-08

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer

Phase 1 Withdrawn

Gynecologic

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

Clinical Trials

LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

iMAGINE

CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)

SMMART Adaptive Clinical Treatment (ACT) Trial

A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)

Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

MARGARET

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma

Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer

Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer

EORTC1615

Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism

Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer

Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer

Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer

Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

PMABIIS

IXO+A in mCRC With Liver-only Metastases

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Proton Therapy With Capecitabine for Rectal Cancer

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer